Company Encyclopedia
View More
name
Caredex
CDNA.US
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
1.946 T
CDNA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking33/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE24.11%A
    • Profit Margin19.68%A
    • Gross Margin69.36%A
  • Growth ScoreB
    • Revenue YoY14.46%B
    • Net Profit YoY145.97%A
    • Total Assets YoY-9.37%E
    • Net Assets YoY13.87%A
  • Cash ScoreB
    • Cash Flow Margin508.15%C
    • OCF YoY14.46%B
  • Operating ScoreB
    • Turnover0.79B
  • Debt ScoreB
    • Gearing Ratio28.03%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CareDx, Inc. (NASDAQ:CDNA) Given Consensus Rating of "Hold" by Brokerages

    CareDx, Inc. (NASDAQ:CDNA) has received a consensus "Hold" rating from nine research firms. Five analysts recommend holding the stock, while four suggest buying. The average 12-month price target is $26.00. Recent analyst actions include Zacks Research upgrading the stock to "Hold" and Wells Fargo lowering its price target to $14.00. CareDx's recent earnings exceeded expectations, with a net margin of 17.97% and revenue up 20.7% year-over-year.

    Market Beat·
    US
    CDNA
    +2.97%
    Market Beat·
    US
    CDNA
    +2.97%

    Craig-Hallum Keeps Their Buy Rating on CareDx (CDNA)

    Craig-Hallum's William Bonello reiterated a Buy rating for CareDx (CDNA) with a $26.00 price target. Bonello, who covers the Healthcare sector, has a 31.6% average return and a 63.47% success rate on stocks. CareDx also received a Buy rating from TR | OpenAI – 4o’s Cira Diagnissa, while H.C. Wainwright maintained a Hold rating.

    Tip Ranks·
    US
    CDNA
    +2.97%
    Tip Ranks·
    US
    CDNA
    +2.97%

    CareDx SHORE Study Shows HeartCare Test Triples Risk Prediction for Heart Transplant Patients

    CareDx Inc. published results from the SHORE study in the Journal of Heart and Lung Transplantation, showing that their HeartCare test significantly increases risk prediction for heart transplant patients. The study analyzed 1,934 patients and found positive HeartCare results linked to higher risks of graft dysfunction and cardiovascular death, even with normal biopsy results. This highlights the test's prognostic value in heart transplant recipients.

    Reuters·
    US
    CDNA
    +2.97%
    Reuters·
    US
    CDNA
    +2.97%

    CareDx Inc. Secretary and General Counsel Jeffrey Adam Novack Reports Disposal of Common Shares

    Jeffrey Adam Novack, Secretary and General Counsel of CareDx Inc., reported the disposal of common shares of the company. The full filing is available through the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. CareDx Inc. published the original content via EDGAR on November 10, 2025.

    Reuters·
    US
    CDNA
    +2.97%
    Reuters·
    US
    CDNA
    +2.97%

    CareDx Inc. to Present at Stephens Investment Conference

    CareDx Inc., a precision medicine company focused on transplant patient solutions, will present at the Stephens Investment Conference in Nashville, TN. A fireside chat is scheduled for November 19, 2025, at 8am CT. This announcement was originally published via Business Wire on November 10, 2025.

    Reuters·
    US
    CDNA
    +2.97%
    Reuters·
    US
    CDNA
    +2.97%
    © 2025 Longbridge｜Disclaimer